Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04230304
Title Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mayo Clinic
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.